To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition.
We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus through April 2011. We also reviewed reference lists and contacted experts to identify candidate studies.
Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo.
We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the
I2 statistic. Results
Fifty-four RCTs were included enrolling over 3400 patients. The quality of the included trials was fair. GH use was associated with statistically significant reduction in weight (WMD, 95% confidence interval (95% CI): −2.31 kg, −2.66 and −1.96) and body fat content (WMD, 95% CI: −2.56 kg, −2.97 and −2.16); increase in lean body mass (WMD, 95% CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95% CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95% CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible.
GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.